Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Ischemic stroke (IS) causes high mortality and severe disability. To improve outcome it's very important to choose the right way of the management of the patient and an appropriate drugs.

There is a large number of the so-called neuroprotective drugs, which were effective in laboratory, but didn't show positive results in clinical studies with using traditional clinical scales scores as a primary outcome measures.

Specialists suggest, that the investigators could receive better results if the investigators change design of the studies, particularly if the investigators select more precise and sensitive method of assessment.

Aim of this study: to determine the role of navigated brain stimulation (NBS) for evaluation of the changes in the motor centers and motor tracts after administration of different cerebroprotective drugs. (The substances won't be compared to each other).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinical Institute of the Brain, Russia
• Collaborators: Ever Neuro Pharma GmbH; Nycomed; Veropharm
• Treatments: Cerebrolysin; Cytidine Diphosphate Choline; Neuroprotective Agents

Criteria

Inclusion Criteria:

• patients from 3 to 6 months after ischemic stroke

• hemispheric infarction

• paresis from 2 to 4 scores by Medical Research Council Weakness Scale (MRC)

Exclusion Criteria:

• history of seizures

• pregnancy, lactation

• cognitive deficiency (poor compliance)

• acute renal failure

• acute hepatic failure

• oncological history

• cardiac pacemakers and other metal implants

• regular intake of any nootropic drugs

• Modified Ashford Scale scores 3 and more

• regular intake of anticonvulsants, neuromuscular relaxants